^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CEP85L (Centrosomal Protein 85 Like)

    i
    Other names: CEP85L, Centrosomal Protein 85 Like, BA57K17.2, NY-BR-15, C6orf204, Serologically Defined Breast Cancer Antigen NY-BR-15, Centrosomal Protein Of 85 KDa-Like, Centrosomal Protein 85kDa-Like, Chromosome 6 Open Reading Frame 204, LIS10
    Associations

    News

    Trials
    over2years
    Detection of exclusive mutations and gene-gene fusions in glioblastoma through analysis of circulating cell-free DNA (cfDNA) as an emerging diagnostic tool (SNO 2023)
    We identified ROS1 fusions (CEP85L-ROS1 and GOPC-ROS1) in 8% of samples, and those might be targeted by crizotinib analogs...Next, we measured cfDNA levels in vitro in response to Temozolomide treatment and discovered a positive correlation between unique 2000bp cfDNA fragments (R=0.8961, P-value=0.015632) and treatment responses in vitro... cfDNA may be used for the detection of exclusive patient mutations and gene fusions and is an emerging diagnostic tool in GBM.
    Cell-free DNA
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR3 (Fibroblast growth factor receptor 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • TACC3 (Transforming acidic coiled-coil containing protein 3) • KDR (Kinase insert domain receptor) • LRP1B (LDL Receptor Related Protein 1B) • SEPTIN14 (Septin 14) • CEP85L (Centrosomal Protein 85 Like)
    |
    TP53 mutation • EGFR mutation • ROS1 fusion • FGFR3 fusion
    |
    Xalkori (crizotinib) • temozolomide
    almost3years
    Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib. (PubMed, Front Oncol)
    The first patient presented with EGFR L858R/L833V compound mutation with MET amplification alongside CEP85L-ROS1 fusion gene, the second with EGFR exon 19del and MKRN1-BRAF fusion, and the last EGFR L858R/V834L compound mutation with MET amplification. Each regimen utilized a tyrosine kinase inhibitor or monoclonal antibody in addition to osimertinib and allowed for a prompt and relatively durable treatment response.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CEP85L (Centrosomal Protein 85 Like)
    |
    EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • ROS1 fusion • MET mutation • BRAF fusion • EGFR L833V • EGFR V834L
    |
    Tagrisso (osimertinib)